The risk of developing cardiovascular disease is strongly associated with bad LDL cholesterol. A large study by scientists at Karolinska Institutet shows that two proteins that transport cholesterol particles in the blood provide early and reliable risk information. The researchers now advocate introducing new guidelines for detecting cardiac risk and say the results may pave the way for early treatment, which could help lower morbidity and fatality rates.
Cardiovascular disease is the most common cause of death globally. It includes various conditions, such as stroke and myocardial infarction with atherosclerosis in different body organs. In many cases, the disease can be prevented and arrested with lifestyle changes and lipid-lowering treatments using statins and other methods.
The data used to assess elevated cardiac risk are reference values for the bad LDL cholesterol. Other fat particles are also measured in some medical conditions and apolipoproteins, which transport cholesterol in the blood. International guidelines for cardiovascular disease recommend using the apolipoprotein apoB, which transports the bad cholesterol, as an alternative risk marker for people with type 2 diabetes, overweight (high BMI) and very high levels of blood lipids.
However, recent research has indicated the importance of factoring in the apolipoprotein apoA-1, transporting the good protective and anti-inflammatory HDL cholesterol. Calculating the apoB/apoA-1 ratio gives a risk quotient reflecting the balance between the bad fat particles that expedite atherosclerosis and the good protective apoA-1 particles that arrest the process.
In this present study, the researchers have analysed the link between cardiovascular disease and apoB/apoA-1 values in more than 137,000 Swedish men and women between 25 and 84. The individuals were followed for 30 years, during which 22,000 suffered some form of a cardiovascular event. The analysis methods are simple, inexpensive and safe, and do not require pre-test fasting, as with LDL and non-HDL tests. Basing their study on an extensive database (AMORIS), the researchers linked the laboratory analyses to several clinical diagnosis registers.
‘The results show that the higher the apoB/apoA-1 value, the greater the risk of myocardial infarction, stroke and need for coronary surgery,’ says Göran Walldius, senior author and professor emeritus at the Institute of Environmental Medicine, Unit of Epidemiology, Karolinska Institutet. ‘The study also showed that the risk was amplified in the presence of low protective levels of apoA-1.’
Individuals with the highest apoB/apoA-1 values had a 70% greater risk of severe cardiovascular disease and almost triple the risk of non-fatal myocardial infarction than those with the lowest apoB/apoA-1 values. Individuals with the highest risk quotient were also more affected by severe cardiovascular diseases many years earlier than individuals with the lowest apoB/apoA-1 values.
The relationship was observed in both men and women, and the elevated levels could be detected as early as 20 years before the onset of cardiovascular disease. ‘Early preventive treatment and information about cardiovascular risk are, of course, important in enabling individuals to manage their risk situation,’ Walldius says. ‘Early treatment can also reduce the cost burden on the public health services.’
All in all, the results indicate that the apoB/apoA-1 ratio is a better marker for identifying more individuals at risk of future cardiovascular disease than the apoB method alone, according to the researchers. ‘It should be possible to introduce cut-values for apoB, apoA-1 and the apoB/apoA-1 ratio into new guidelines as a complement to current guidance on the detection and treatment of dyslipidaemia,’ Walldius says. The study was financed by the Gunnar and Ingmar Jungner Foundation for Laboratory Medicine.